^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GEN1044

i
Other names: GEN1044, DuoBody-CD3x5T4, ABBV-GEN1044, ABBV-GMAB-1044
Associations
Trials
Company:
AbbVie, Genmab
Drug class:
CD3 agonist, 5T4 inhibitor
Related drugs:
Associations
Trials
2years
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models. (PubMed, Life Sci Alliance)
Lastly, in dissociated patient-derived tumor samples, DuoBody-CD3x5T4 activated tumor-infiltrating lymphocytes and induced tumor-cell cytotoxicity, even when most tumor-infiltrating lymphocytes expressed PD-1. These data provide an in-depth view on the mechanism of action of a CD3 bsAb in preclinical models of solid cancer.
PK/PD data • Preclinical • Journal
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • GZMB (Granzyme B) • IFNGR1 (Interferon Gamma Receptor 1)
|
PD-1 expression
|
GEN1044